Clinical Trials Monitor/
RecruitingNCT07420790

Designing a Generative AI Model and Propensity Score Matching Methodology for Validation of "The Phase II Study on Venetoclax (VEN) Plus Decitabine (DEC) (VEN-DEC) in Elderly (e60 <75years) Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Eligible for Allogeneic Stem Cell Transplantation (Allo-SCT)". Evaluation of an Exploratory Approach Respect to a Randomized Phase III Trial

Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Trial Details

ConditionAcute Myeloid Leukemia
StatusRecruiting
Participants1,941
Est. Completion1 July 2026
Last Updated30 Apr 2026

Primary Outcome

Propensity Score Matching (PSM) objective; Artificial Intelligence objectives

Eligibility Criteria

Inclusion Criteria

Inclusion Criteria: * Patients with AML treated with cht (historical cohort) or VenDec (experimental cohort) Exclusion Criteria: \-

Trial Sites

Countries

Italy
View Registry Entry

Related Analysis

Phase II AML Trial Pioneers AI-Driven Propensity Score Matching to Validate Venetoclax-Decitabine in Transplant-Eligible Elderly Patients

Italian researchers pioneer AI-driven propensity score matching to validate venetoclax-decitabine therapy in elderly AML patients eligible for transplant. This innovative methodology could revolutionise clinical trial design in haematological malignancies.

Read full article →

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service